XTL Biopharmaceutica (Israel) Probability of Target Price Finishing Over Current Price

    XTLB -- Israel Stock  

    ILS 9.60  0.40  4.35%

    XTL Biopharmaceutica probability of target price tool provides mechanism to make assumptions about upside and downside potential of XTL Biopharmaceuticals Ltd performance during a given time horizon utilizing its historical volatility. Please specify XTL Biopharmaceutica time horizon, a valid symbol (red box) and a target price (blue box) you would like XTL Biopharmaceutica odds to be computed. See also Your Current Watchlist.
    Horizon     30 Days    Login   to change
    Refresh Odds

    XTL Biopharmaceutica Target Price Odds to finish over

    Current PriceHorizonTarget PriceOdds to move above current price in 30 days
     9.60 30 days 9.60  ABOUT 6.93%
    Based on normal probability distribution, the odds of XTL Biopharmaceutica to move above current price in 30 days from now is about 6.93% (This XTL Biopharmaceuticals Ltd probability density function shows the probability of XTL Biopharmaceutica Stock to fall within a particular range of prices over 30 days) .
    Assuming 30 trading days horizon, XTL Biopharmaceuticals Ltd has beta of -0.616 . This means as returns on benchmark increase, returns on holding XTL Biopharmaceutica are expected to decrease at a much smaller rate. During bear market, however, XTL Biopharmaceuticals Ltd is likely to outperform the market. In addition to that XTL Biopharmaceuticals Ltd has an alpha of 2.3198 implying that it can potentially generate 2.3198% excess return over DOW after adjusting for the inherited market risk (beta).
     XTL Biopharmaceutica Price Density 
    Current Price   Target Price   
    Alpha over DOW
    Beta against DOW=0.62
    Overall volatility
    Information ratio =0.30

    XTL Biopharmaceutica Alerts

    XTL Biopharmaceutica Alerts and Suggestions

    XTL Biopharmaceutica is not yet fully synchronised with the market data
    XTL Biopharmaceutica appears to be very risky and stock price may revert if volatility continues
    XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years
    XTL BIOPHARMAC has accumulated about 5.54 M in cash with (1.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
    See also Your Current Watchlist. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
    Search macroaxis.com